Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by ...

Chronic Kidney Disease (CKD) affects approximately 15% of U.S. adults and as many as 9 in 10 with CKD are unaware they have ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

People with a complex heart, kidney and metabolic-related condition who got better quality sleep were less likely to have an ...

Anyone who has diabetes, high blood pressure, heart problems or has a family history of the disease is at increased risk for ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...